Additionally, the presence of CKD, whether pre-existing or newly developed post-transplant, compounds the challenges faced by these patients, creating a double hit scenario that further complicates their management
Last reviewed: May 22, 2026 Last updated: May 22, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
781 Graue, M
doi: 10.1038/s41589-020-0472-6 25 ZhengJConradM
In another phase 3 analysis, retatrutide at the highest dose reached up to 28.7% weight loss, making it the most potent weight loss medication ever tested in large-scale clinical trials